Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Syndax Pharmaceuticals (SNDX) Interest Expenses (2020 - 2025)

Syndax Pharmaceuticals has reported Interest Expenses over the past 6 years, most recently at $4000.0 for Q2 2025.

  • For Q2 2025, Interest Expenses fell 91.11% year-over-year to $4000.0; the TTM value through Mar 2026 reached $4000.0, up 107.41%, while the annual FY2025 figure was $6000.0, 700.0% up from the prior year.
  • Interest Expenses for Q2 2025 was $4000.0 at Syndax Pharmaceuticals, up from $2000.0 in the prior quarter.
  • Over five years, Interest Expenses peaked at $1.7 million in Q3 2022 and troughed at -$124000.0 in Q4 2024.
  • A 5-year average of $293388.9 and a median of $54000.0 in 2023 define the central range for Interest Expenses.
  • Biggest five-year swings in Interest Expenses: surged 714.29% in 2022 and later crashed 296.83% in 2024.
  • Year by year, Interest Expenses stood at -$7000.0 in 2021, then soared by 714.29% to $43000.0 in 2022, then soared by 46.51% to $63000.0 in 2023, then crashed by 296.83% to -$124000.0 in 2024, then soared by 103.23% to $4000.0 in 2025.
  • Business Quant data shows Interest Expenses for SNDX at $4000.0 in Q2 2025, $2000.0 in Q1 2025, and -$124000.0 in Q4 2024.